Comparison of outcomes of a two drug versus a single drug regimen in women undergoing IVF
Not Applicable
- Conditions
- Health Condition 1: N978- Female infertility of other originHealth Condition 2: N971- Female infertility of tubal originHealth Condition 3: N979- Female infertility, unspecified
- Registration Number
- CTRI/2020/08/027030
- Lead Sponsor
- Dr Aryan Kashyap
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1Patients willing to participate
2Age - 21 to 38 years (both included)
3Tubal factor infertility
4Male factor infertility
5Unexplained infertility
6Normal ovarian reserve â?? A baseline Antral follicle count between 5-15(both of which are included)
Exclusion Criteria
1Patients with Polycystic Ovarian syndrome
2Patients with Endocrine disorders â?? Diabetes Mellitus, uncorrected hypothyroidism, Hyperprolactinemia, congenital adrenal hyperplasia
•Patients with Thin endometrium ( < 6 mm)
•Previous History of uterine surgeries, adhesiolysis, myomectomy and adenomyosis
•Poor Ovarian reserve (AFC < 5 or serum Anti Mullerian Hormone levels < 1.2 ng/ml)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Number of Metaphase II oocytes retrieved <br/ ><br>2.Number of good quality embryos <br/ ><br>Timepoint: 1. At time of Oocyte retreival <br/ ><br>2. At time of Embryo transfer
- Secondary Outcome Measures
Name Time Method 1.Determination of Luteinizing hormone levels twelve hours post trigger <br/ ><br>2.Implantation rates in both the group <br/ ><br> 3. Number of embryos frozen <br/ ><br>Timepoint: 1.12 hours after trigger administration <br/ ><br>2. 14 days after Embryo transfer <br/ ><br>3. AT time of embryo transfer